Luc R C W van Lonkhuijzen
Overview
Explore the profile of Luc R C W van Lonkhuijzen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
303
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brink G, Groeneweg J, Sickinghe A, Nijman H, van Lonkhuijzen L, Lok C, et al.
J Ovarian Res
. 2025 Feb;
18(1):37.
PMID: 39987174
Background: As current literature does not provide sufficient data to support clear guidelines in patients with a rare adult-type granulosa cell tumor, we aim to investigate: (1) whether additional staging...
2.
Van Bommel M, Steenbeek M, IntHout J, Van Garderen T, Harmsen M, Arts-De Jong M, et al.
BJOG
. 2025 Jan;
PMID: 39823150
Objective: To compare menopause-related quality of life (QoL) after risk-reducing salpingectomy (RRS) versus risk-reducing salpingo-oophorectomy (RRSO) until 3 years of post-surgery. Design: A prospective study (TUBA study) with treatment allocation...
3.
Schoonhoven F, Aarts J, Fons G, Stalpers L, van Lonkhuijzen L, van der Velden J, et al.
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796654
Background: Guidelines recommend the extension of the pelvic radiotherapy volume to the para-aortic region in locally advanced cervical cancer and ≥3 suspicious pelvic lymph nodes (PLN) on imaging. Whether this...
4.
Vos J, Caroline Vos M, van Lonkhuijzen L, van de Poll-Franse L, Ezendam N
Gynecol Oncol
. 2024 Dec;
192():178-180.
PMID: 39674134
No abstract available.
5.
Stroot I, Bart J, Hollema H, Wagner M, Yigit R, van Doorn H, et al.
J Natl Cancer Inst
. 2024 Nov;
PMID: 39579093
Background: Risk-reducing salpingo-oophorectomy (RRSO) effectively prevents high-grade serous carcinoma (HGSC) in BRCA1/2 germline pathogenic variant (GPV) carriers. Still, some women develop HGSC after RRSO without pathologic findings. This study assessed...
6.
Ng Z, Manchanda R, Lopez A, Obermair A, Dostalek L, Pareja R, et al.
Gynecol Oncol
. 2024 Oct;
191:95-99.
PMID: 39378742
Objective: Patients with TNM T1a cervical cancer have excellent prognosis; however, the risk for recurrence remains an issue of concern and management guidelines are based on limited data. Here we...
7.
Brouwer C, Hartman Y, Stelten S, Kenkhuis M, van Lonkhuijzen L, Kenter G, et al.
Int J Gynecol Cancer
. 2024 Sep;
PMID: 39244208
Objective: Chemotherapy treatment modifications can impact survival in patients with ovarian cancer, particularly when the relative dose intensity falls below 85%. Exercise and dietary interventions may benefit treatment tolerability. This...
8.
Luijten M, Van Weelden W, Lalisang R, Bulten J, Lindemann K, van Beekhuizen H, et al.
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893205
Background: Response to hormonal therapy in advanced and recurrent endometrial cancer (EC) can be predicted by oestrogen and progesterone receptor immunohistochemical (ER/PR-IHC) expression, with response rates of 60% in PR-IHC...
9.
Stroot I, Bart J, Hollema H, Jalving M, Wagner M, Yigit R, et al.
Gynecol Oncol
. 2024 May;
187:198-203.
PMID: 38795508
Objective: The aim of this study was to describe the long-term outcome of asymptomatic BRCA1/2 germline pathogenic variant (GPV) carriers with high-grade serous carcinoma (HGSC) in their risk-reducing salpingo-oophorectomy (RRSO)...
10.
Seeratan D, van Schuylenburch R, van Lonkhuijzen L, Aarts J
Support Care Cancer
. 2024 Mar;
32(4):247.
PMID: 38528152
Purpose: The purpose of this study was to explore ovarian cancer patients' preferences regarding follow-up care and, in particular, the use of patient-reported outcome measures (PROMs) as an approach to...